retatrutide phase 2 diabetes weight loss 2024 Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, 3 Retatrutide study sees significant weight

Comparing private and NHS access The trade-off between NHS and private weight-loss medication is mostly between cost and waiting time

Four states had eliminated obesity drug coverage entirely

Nutrient-rich foods These concerns are all valid, but instances of the rebound effect highlighted in the western press have been due to patients returning to their former eating habits when they stop taking the drug

Book Now GLP-2 30 mg vialdual GIP/GLP-1 receptor agonist for appetite control, glucose support, and weight management

Is a GLP-1 injection like insulin

Statins reduce LDL cholesterol by 3050%, whilst GLP-1 agents achieve only modest reductions of 17%, and are not licensed for dyslipidaemia treatment